Advertisements



TG Therapeutics reports triple therapy data from Phase I/II study of ublitux

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 8th, 2019

Denali Therapeutics reports three-month data from Phase 1/2 study of ETV:IDS

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 12th, 2021

Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress

- Positive early safety and efficacy data with nomacopan Phase II clinical study in patients with mild-to-moderate bullous pemph.....»»

Category: earningsSource: benzingaAug 29th, 2019

Aptevo Therapeutics Reports Second Quarter 2019 Financial Results

Reports Positive Preliminary Top-Line Safety Data for APVO210Phase 1 Single Ascending Dose (SAD) Clinical Study Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD) Study Co.....»»

Category: earningsSource: benzingaAug 9th, 2019

Applied Therapeutics reports AT-007 SAD data from Phase 1/2 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 8th, 2019

Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019

-Announced positive Phase 3 results from LIBERTY 1 study evaluating relugolix combination therapy in women with uterine fibroids- -Data from four additional Phase 3 clinical studies ex.....»»

Category: earningsSource: benzingaMay 24th, 2019

Nightstar Therapeutics Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third Quarter 2018

Preliminary data from dose escalation study in the Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigm.....»»

Category: earningsSource: benzingaJun 6th, 2018

Anika Reports Top Line Data from CINGAL Study, Shares Slump

Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee. Sha.....»»

Category: smallbizSource: nytJun 21st, 2018

Seres Therapeutics announces presentation of Phase 3 Ecospor III study data

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 21st, 2021

Silence Therapeutics announces data from GEMINI Phase 1 study of SLN124

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 19th, 2021

Aptinyx reports "positive" data from Phase 2 study of NYX-783

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 29th, 2021

Trillium Therapeutics provides data update on Phase 1 study of TTI-621

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 28th, 2021

Trillium Therapeutics provides data update on Phase 1 study of TTI-622

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 28th, 2021

Yumanity Therapeutics announces data from Phase 1a MAD study of YTX-7739

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 22nd, 2021

Turning Point reports Phase 1/2 SWORD-1 study data of TPX-0046

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 5th, 2021

BrainStorm reports "positive" data in Phase 2 study evaluating NurOwn

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 24th, 2021

Epizyme reports preliminary data from Phase 1b/3 study of EZH-302

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 2nd, 2021

Epizyme reports preliminary data from Phase 1b/2 study of EZH-1101

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 2nd, 2021

Frequency Therapeutics reports publication of FX-322 Phase 1/2 study results

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 22nd, 2021

Spark Therapeutics announces data from Phase 1/2 hemophilia A study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 5th, 2021

Seneca Biopharma reports data from Phase 2 study of NSI-566 in China

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 20th, 2021